Literature DB >> 17619882

Quantitative secretin MRCP (MRCPQ): results in 215 patients with known or suspected pancreatic pathology.

A R Gillams1, W R Lees.   

Abstract

Secretin magnetic resonance cholangiopancreatography quantification (MRCPQ) of pancreatic exocrine function correlates well with steatorrhoea and conventional, non-invasive function tests. We report MRCPQ results in a variety of pancreatic conditions. A total of 215 patients [107 male, mean age 46 years (14-78)] were studied. A multi-slice MRCP sequence was performed before and at 2-min intervals after 0.1 ml/kg IV secretin. Change in small intestinal water volume was plotted against time and the flow rate derived from the gradient. Patients were classified using clinical history, MRCP, MR imaging, computed tomography (CT) [150/215 (70%)] and endoscopic retrograde cholangiopancreatography (ERCP) [56/215 (26%)] findings but not MRCPQ results. Mean, standard deviation and 95% confidence intervals were calculated. The one way ANOVA and Student's t-test were used for statistical analysis. Seventy-six patients had chronic pancreatitis, 26 were post-surgical, 34 post-acute pancreatitis, six atrophic pancreatopathy, eight with obstruction, 15 divisum, ten sphincter of Oddi dysfunction, 26 normal and 14 miscellaneous. Significant differences were observed between normals (mean+/-SD; 7.4 +/- 2.9 ml/min) and severe chronic pancreatitis (5.3 +/- 2.4) (P = 0.018), pancreatic atrophy (3.8 +/- 3.1) (P = 0.013) or duct obstruction (5.3 +/- 2.4) (P = 0.047)) and between moderate (7.0 +/- 3.0) (P = 0.03) and severe chronic pancreatitis. MRCPQ can be used to quantify function across the spectrum of pancreatic disease and showed significant differences between several different pathologies.

Entities:  

Mesh:

Year:  2007        PMID: 17619882     DOI: 10.1007/s00330-007-0708-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  16 in total

1.  MR hydrometry to assess exocrine function of the pancreas: initial results of noninvasive quantification of secretion.

Authors:  J T Heverhagen; D Müller; A Battmann; N Ishaque; D Boehm; M Katschinski; H J Wagner; K J Klose
Journal:  Radiology       Date:  2001-01       Impact factor: 11.105

2.  Quantification of pancreatic exocrine function with secretin-enhanced magnetic resonance cholangiopancreatography: normal values and short-term effects of pancreatic duct drainage procedures in chronic pancreatitis. Initial results.

Authors:  M A Bali; A Sztantics; T Metens; M Arvanitakis; M Delhaye; J Devière; C Matos
Journal:  Eur Radiol       Date:  2005-07-01       Impact factor: 5.315

3.  Comparison of two tubeless function tests in the assessment of mild-to-moderate exocrine pancreatic insufficiency.

Authors:  A Leodolter; S Kahl; J E Domínguez-Muñoz; C Gerards; B Glasbrenner; P Malfertheiner
Journal:  Eur J Gastroenterol Hepatol       Date:  2000-12       Impact factor: 2.566

4.  Non-invasive quantification of pancreatic exocrine function using secretin-stimulated MRCP.

Authors:  S Punwani; A R Gillams; W R Lees
Journal:  Eur Radiol       Date:  2002-08-06       Impact factor: 5.315

5.  Pancreatic duct: morphologic and functional evaluation with dynamic MR pancreatography after secretin stimulation.

Authors:  C Matos; T Metens; J Devière; N Nicaise; P Braudé; G Van Yperen; M Cremer; J Struyven
Journal:  Radiology       Date:  1997-05       Impact factor: 11.105

6.  Faecal elastase 1: not helpful in diagnosing chronic pancreatitis associated with mild to moderate exocrine pancreatic insufficiency.

Authors:  P G Lankisch; I Schmidt; H König; D Lehnick; R Knollmann; M Löhr; S Liebe
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

7.  Pancreolauryl test for pancreatic exocrine insufficiency.

Authors:  M Ventrucci; L Gullo; C Daniele; P Priori; G Labò
Journal:  Am J Gastroenterol       Date:  1983-12       Impact factor: 10.864

8.  Fecal elastase 1 determination in chronic pancreatitis.

Authors:  L Gullo; M Ventrucci; P Tomassetti; M Migliori; R Pezzilli
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

9.  Severe chronic pancreatitis versus suspected pancreatic disease: dynamic MR cholangiopancreatography after secretin stimulation.

Authors:  R Manfredi; G Costamagna; M G Brizi; G Maresca; A Vecchioli; C Colagrande; P Marano
Journal:  Radiology       Date:  2000-03       Impact factor: 11.105

10.  Limitations of faecal elastase-1 and chymotrypsin as tests of exocrine pancreatic disease in adults.

Authors:  W G Brydon; K Kingstone; S Ghosh
Journal:  Ann Clin Biochem       Date:  2004-01       Impact factor: 2.057

View more
  6 in total

1.  Secretin-Enhanced MRCP: How and Why-AJR Expert Panel Narrative Review.

Authors:  Jordan Swensson; Atif Zaheer; Darwin Conwell; Kumar Sandrasegaran; Riccardo Manfredi; Temel Tirkes
Journal:  AJR Am J Roentgenol       Date:  2021-03-11       Impact factor: 3.959

Review 2.  Diagnosing Chronic Pancreatitis.

Authors:  Ahmad Anaizi; Phil A Hart; Darwin L Conwell
Journal:  Dig Dis Sci       Date:  2017-03-17       Impact factor: 3.199

Review 3.  The clinical value of secretin-enhanced MRCP in the functional and morphological assessment of pancreatic diseases.

Authors:  Bella Chamokova; Nina Bastati; Sarah Poetter-Lang; Yesim Bican; Jacqueline C Hodge; Martin Schindl; Celso Matos; Ahmed Ba-Ssalamah
Journal:  Br J Radiol       Date:  2018-02-05       Impact factor: 3.039

Review 4.  The diagnosis and management of Sphincter of Oddi dysfunction: a systematic review.

Authors:  Thomas C Hall; Ashley R Dennison; Giuseppe Garcea
Journal:  Langenbecks Arch Surg       Date:  2012-06-13       Impact factor: 3.445

Review 5.  Quantitative pancreatic MRI: a pathology-based review.

Authors:  Manil D Chouhan; Louisa Firmin; Samantha Read; Zahir Amin; Stuart A Taylor
Journal:  Br J Radiol       Date:  2019-06-14       Impact factor: 3.039

Review 6.  Acute recurrent pancreatitis: Etiopathogenesis, diagnosis and treatment.

Authors:  Pier Alberto Testoni
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.